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1. Introduction 
Although it is generally recognized that the long-term clinical outcome of bare-metal stents 
(BMS) is favorable, a late luminal narrowing with restenosis of BMS can occur during the 
extended follow-up (beyond 5 years), resulting in clinical events such as stent thrombosis 
and myocardial infarction. Regarding the mechanisms of progressive late luminal 
renarrowing, a persistent and remarkable foreign body inflammatory reaction to the metal 
may promote new atherosclerotic changes and consequent plaque vulnerability of the 
neointimal tissue around the stent struts. However, neointimal atherosclerotic change 
(neoatherosclerosis) after BMS implantation is rarely reported. Although drug-eluting stents 
(DES) have dramatically reduced restenosis and target lesion revascularization compared 
with BMS, long-term safety remains a clinical major concern due to persistent increase in the 
incidence of very late stent thrombosis (VLST). While stent thrombosis is a multifactorial 
process, it has shown that tissue coverage over stent struts is an important determinant of 
late stent thrombosis. Furthermore, the development of neoatherosclerosis inside the DES 
may be another rare mechanism of late thrombotic events. Neoatherosclerosis in DES (two 
years after implantation) can occur earlier than in BMS. Because of high resolution up to 10 
μm, it has been described that optical coherence tomography (OCT) has the potential to 
identify the features of unstable plaques such as thin fibrous cap, large lipid core, thrombus, 
macrophage infiltration, and neovascularization. Furthermore, even in the evaluation of 
stent, OCT has been reported to be able to demonstrate the stented lesion morphology in 
detail including tissue protrusion, thrombus formation, incomplete apposition, late acquired 
malaposition, edge dissection, tissue coverage over struts, and so on. This chapter describes 
about the assessment of neoatherosclerosis within BMS and DES by OCT. 
2. Late vascular healing response to bare-metal stent 
Coronary stenting is an effective strategy to prevent restenosis in atherosclerotic lesions as 
compared to balloon angioplasty. Bare-metal stent (BMS) is widely used in the 
interventional cardiology. It has been reported that in-stent restenosis (ISR) after BMS 
implantation, especially late ISR, is not always benign and late ISR is closely associated with 
mortality. Furthermore, progressive increases in the incidence of late target lesion 
revascularization (TLR) is observed beyond 4 years and up to 15 to 20 years after BMS 
implantation. A serial angiographic follow-up study of BMS has demonstrated several 
phases, with early restenosis phase until the first 6 months, stabilization and regression 
phase from 6 months to 3 years, and late luminal renarrowing phase beyond 4 years. With 
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regard to the mechanisms of progressive late luminal renarrowing, Inoue et al. reported the 
pathological findings within the BMS. Three years after BMS implantation, apparent chronic 
inflammatory cell infiltration (mainly T lymphocytes) and neovascularization are 
recognizable around the stent struts, and beyond 4 years, heavy infiltration of foamy cells 
(lipid-laden macrophages) is observed. The authors concluded that stainless steel stents 
evoke a remarkable foreign body inflammatory reaction to the metal and persistent peri-
strut chronic inflammatory cells may accelerate new atherosclerotic changes and consequent 
plaque vulnerability of the neointimal tissue around the stent struts. Although the precise 
incidence of new atherosclerosis during an extended follow-up after BMS implantation is 
unknown, several papers report the features in neointima (Table 1).  
Yokoyama et al serially evaluated the detailed changes inside the BMS by using angioscopy. 
Between the first follow-up (6 to 12 months) and the second follow up (≥ 4 years), the 
frequencies of lipid-laden yellow plaque and thrombus increased from 12% (3 of 26 patients) 
to 58% (15 of 26 patients) and from 4% to 31%, respectively. BMS segments with yellow 
plaque were significantly associated with late luminal narrowing. 
OCT (LightLab Imaging, Westford, MA, USA) is an intracoronary imaging modality with a 
high-resolution of 10 to 20 μm, providing detailed information about microstructures such 
as thin fibrous cap as well as the histology. Furthermore, OCT has the greatest advantage in 
its accuracy of tissue characterization compared with other coronary imaging modalities. 
Recently, using OCT, Takano et al observed the differences in neointima between early 
phase (< 6 months) and late phase (≥ 5 years). When compared with normal neointima (Fig. 
1) proliferated homogeneously in the early phase, neointima within the BMS ≥ 5 years after 
implantation was characterized by marked signal attenuation and a diffuse border, 
suggesting lipid-laden intima (Fig. 2). Its frequency was 67% and lipid-laden intima was not 
observed in the early phase. Thin-cap fibroatheroma (TCFA)-like intima (Fig. 3) was 
observed in 29% of the patients in the late phase. Intimal disruption (Fig. 4) and thrombus 
(Fig. 5) were found frequently in the late phase as compared with the early phase (38% vs. 
0% and 52% vs. 5%, respectively; p < 0.05). However, there was no significant difference in 
terms of calcification (Fig. 6) between the 2 phases (10% vs. 0%). Although there was no 
significant difference with respect to the incidence of peristent neovascularization (Fig. 7A) 
between the 2 phases (81% vs. 60%, p = 0.14), intraintima neovascularization (Fig. 7B) was 
observed more frequently in the late phase than in the early phase (62% vs. 0%, p < 0.01) and 
in segments with lipid-laden intima than those in without lipid-laden intima (79% vs. 29%, p 
= 0.026). Furthermore, lipid-laden intima was more frequent in “symptomatic” patients than 
in asymptomatic patients. The frequencies of late ISR (62% vs. 0%, p < 0.001) and late TLR 
(62% vs. 0%, p < 0.001) were higher in patients with lipid-laden intima as compared with 
those without lipid-laden intima. Four patients with acute coronary syndrome in the late 
phase had both intimal disruption and thrombus. The authors speculated that 
neovascularization expanding from the peristent area into the intima with time might play a 
key role in atherosclerosis progression and the instability of neointimal tissue, as well as 
plaque neovascularization of nonstent segments in native coronary arteries. Hou et al also 
performed angiographic and OCT examinations in 39 patients with recurrent ischemia 
among 1636 patients who underwent BMS implantation. The average time interval between 
initial BMS implantation and OCT imaging was 6.5±1.3 years. Of 60 stents in 39 patients, 20 
stents (33.3%) in 16 patients had OCT-derived lipid-rich plaques inside the stents. In 13 of 
these 20 stents, angiographic ISR was observed, and 7 restenotic lesions with lipid-rich  
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Table 1. Neoatherosclerosis inside the implanted stent. BMS, bare-metal stent; DES, drug-
eluting stent; ISR, in-stent restenosis; N.A., not applicable; OCT, optical coherence 
tomography; TCFA, thin-cap fibroatheroma; * Surface irregularity; ** Minimum lumen area 
site; Any neoatherosclerosis. 
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plaque manifested clinical presentations of unstable angina. Six lipid-rich plaques had 
evidence of intimal disruption. However, thrombus was found in only one stent (5%). Notably, 
7 (35%) of 20 lipid-rich plaques had features consistent with macrophage infiltration (Fig. 8). 
More recently, Habara et al evaluated the difference of tissue characteristics between early 
(within the first year) and very late (> 5 years, without restenosis within the first years) 
restenostic lesions after BMS implantation by OCT. The mean follow-up period of early and 
very late ISR was 8.7±4.1 months and 113.8±29.6 months, respectively. The morphological 
characteristics of restenostic tissue (characterized by heterogeneous intima) in very late ISR  
 
Fig. 1. Normal neointima inside the stent. OCT image of normal neointima showing a 
homogenous signal-rich band without signal attenuation. 
 
Fig. 2. Lipid-laden neointima inside the stent. OCT image of a neointima with lipid 
component showing a signal-poor region with poorly delineated border (*). In this area, the 
stent struts are invisible. 
 
Fig. 3. Thin-cap fibroatheroma-like neointima inside the stent. Thin-cap fibroatheroma-like 
intima is defined as a lipidic tissue (*) with a thin fibrous cap measuring < 65 μm. 
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Fig. 4. Neointimal rupture inside the stent. OCT image of a neointimal rupture showing the 
disruption of fibrous cap (arrow) and cavity formation (*) within well expanded struts 
(arrowheads). 
 
 
 
Fig. 5. Intracoronary thrombus inside the stent. OCT image of an intracoronary thrombus 
(arrow) showing a mass protruding into the vessel lumen.  
 
 
Fig. 6. Calcification inside the stent. OCT image of a calcification (*) showing a signal-poor 
region with sharply delineated border. 
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Fig. 7. Neovascularization inside the stent. (A) OCT image of peristent micro-vessels 
(arrows) showing a cluster of no-signal small vesicular and tubular structures locating 
around the struts. (B) OCT image of intraintima micro-vessels (arrows) showing small black 
holes locating near the vessel lumen within the neotintimal tissue. 
 
Fig. 8. Macrophage infiltration in neointima inside the stent. OCT image of macrophage 
infiltration showing a linear high-brightness region with shadowing behind (arrows). 
were different from those (characterized by homogeneous intima) in early ISR and 
consistent with atherosclerotic plaque. In the very late ISR group, 31 (72.1%) of 43 patients 
underwent TLR. Notably, 17 patients (39.5%) had been asymptomatic until the follow-up 
angiography. These previous studies suggest that new atherosclerotic plaque formation in 
neointima may occur during an extended follow-up period after BMS implantation and 
contribute to clinical coronary events such as very late stent thrombosis. Even when the 
patients remain clinically stable and asymptomatic until their late follow-up presentations, 
unstable features such as TCFA and rupture may develop within the implanted BMS (Fig. 
9). Therefore, a long-term optimal medical therapy including statins and a good control of 
coronary risk factors for secondary prevention will be needed to prevent such complications 
in patients who have previously undergone BMS implantation. 
3. Vascular healing response to drug-eluting stent 
Although drug-eluting stents (DES) have dramatically reduced restenosis and target lesion 
revascularization compared with BMS, long-term safety remains a clinical major concern 
because of persistent increase in the incidence of very late stent thrombosis (VLST). VLST in 
DES, after the first year, was reported at rates of 0.2-0.6% per year up to 3 years and the 
recommendations for dual antiplatelet therapy consisting of aspirin and thienopyridines 
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Fig. 9. A case with thin-cap fibroatheroma-like intima and neointimal rupture inside the 
bare-metal stent. A 57-year-old man was given a diagnosis of anterior ST-segment elevation 
myocardial infarction and treated with a 4.0X18 mm bare-metal stent (BMS) implanted to 
the proximal-portion of the left anterior descending artery (LAD) 6 years ago. A scheduled 
follow-up coronary angiography at 6 months after the index procedure demonstrated no 
restenosis. Six years after stent implantation, he suddenly presented with chest pain at rest 
and was admitted to the hospital. An emergent coronary angiography showed total 
occlusion of the right coronary artery (A, arrow), severe stenosis in the mid-portion of the 
left circumflex artery (B, arrow), and no in-stent restenosis of the previously implanted BMS 
of the LAD (B, dotted line). After successful reperfusion therapy of the RCA, optical 
coherence tomography (OCT) was performed in the LAD. OCT revealed thin-cap 
fibroatheroma-like intima (C) and neointimal rupture (D) inside the previous BMS. Many 
stent struts are invisible due to marked signal attenuation, representing lipid component (*). 
In this patient, medical control for secondary prevention was insufficient (low-density 
lipoprotein cholesterol level was 174mg/dL and hemoglobin A1c was 11.8%). Arrowheads 
indicate stent struts. 
were extended to ≥ 12 months after DES implantation without a clear evidence wether this 
extension would reduce the rates of VLST. Although stent thrombosis is a multifactorial, 
Finn et al has reported that inadequate stent coverage (the ratio of uncovered struts to 
total struts) is a powerful histological predictor of late stent thrombosis. OCT can reliably 
distinguish thin neointimal hyperplasia (< 100 μm) on stent struts and uncovered struts, 
which is undetectable by intravascular ultrasound (IVUS). It has also been reported that 
OCT imaging can accurately assess the extent and thickness of neointimal coverage on 
stent struts after stent implantation with good histological correlation. Xie et al. 
performed OCT imaging at 3 months after sirolimus-eluting stent (SES) implantation. In 
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this study, the frequencies of uncovered struts and struts with neointimal coverage < 100 
μm were 15 % and 94 %, respectively. Matsumoto et al. also investigated 34 patients with 
SES who underwent OCT examination at 6 months after implantation. Eleven % of struts 
still remained uncovered. Only 9 SESs (16%) demonstrated full coverage by neointima, 
whereas the remaining stents had partially uncovered struts. Yao et al, by using OCT, 
evaluated the time course of neointimal coverage in SES after implantation. Between 6 
months and 12 months, the frequency of uncovered struts decreased from 9.2% to 6.6%. 
Katoh et al also reported a comparison of OCT findings in identical SES at 6 months and 
12 months. As a result, the frequency of struts without neointimal coverage (10.4% to 
5.7%) was similar to the results of Yao’s study. Furthermore, Takano et al. serially 
performed OCT imaging at 2 and 4 years after implantation in 17 patients treated with 21 
SESs. The frequency of patients with uncovered struts significantly decreased from 88% to 
29% (p = 0.002). The presence of mural thrombus might be one of risk factors for stent 
thrombosis. Otake et al reported that mural thrombus was detected in 14 (26%) of 53 
lesions by OCT at 6 months after SES implantation. Subclinical thrombus was associated 
with larger number of uncovered struts, uneven neointimal thickness, greater asymmetric 
stent expansion, and longer SES. However, in this small study, the presence of mural 
thrombus did not lead to clinical stent thrombosis during follow-up period (median 485 
days). Kim et al also reported a large-scale OCT registry data of 226 patients with various 
DESs. The frequencies of intracoronary thrombus were 28% in SES, 11% in paclitaxel-
eluting stent (PES), and 1% in zotarolimus-eluting stent (ZES), respectively. Although the 
presence of intracoronary thrombus was associated with longer stent length (≥ 28mm), 
smaller stent diameter (< 3.0 mm), and more uncovered struts (≥ 8 uncovered struts in 
each stent), major adverse cardiac events including stent thrombosis were not found in 
patients with intracornary thrombus during follow-up period (mean 8 months). These 
studies demonstrate that there is a relationship between uncovered stent struts and 
thrombus formation. However, to obtain clear conclusion about clinical implications of 
subclinical thrombus detected by OCT, further studies with long-term clinical follow-up 
and larger population are warranted. 
Late-acquired incomplete stent apposition (ISA) may also be one of main mechanisms of 
VLST of DES. One IVUS observational study demonstrated its possible association with 
VLST after DES implantation. The mechanism of late-acquired ISA is widely accepted to 
typically be the result of either positive arterial remodeling and/or thrombus dissolution 
behind the stent struts (especially in myocardial infarction). Although the clinical 
association of late-acquired ISA and stent thrombosis remains controversial and is under 
intense investigation, Ozaki et al. assessed the fate of ISA post-SES implantation by using 
OCT. The frequency of incompletely apposed struts post-intervention was 7.2% (309 
struts). Of 309 struts, 202 (65%) struts remained persistent ISA without neointimal 
coverage even at 10-month follow-up. Mural thrombus was observed more frequently in 
struts with ISA (20.6%) compared with struts with a good apposition (only 2.0%). Thus, it 
has been suggested that the underlying mechanism of VLST may be different between 
BMS and DES. However, chronic inflammatory can occur in DES as well as BMS and may 
be more pronounced with DES due to the presence of the polymer carrying therapeutic 
drug. This high degree of inflammation can develop neoatherosclerosis with shorter 
implant duration in DES than in BMS. More recently, it has been reported that the 
development of neoatherosclerosis may be an additional contributing factor to very late 
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thrombotic events in DES. Kang et al demonstrated the results of OCT analysis of in-stent 
neoatherosclerosis in 50 patients with ISR after DES implantation. The median follow-up 
period was 32.2 months (9.2 to 52.2). Twenty (40%) of 50 patients presented with unstable 
angina and the remaining 30 (60%) patients with stable angina. Despite clinical 
presentations of unstable or stable angina, 90% of the lesions had lipid-laden neointima. 
Fifty-two % of the lesions had at least 1 TCFA-like neointima and 58% had at least 1 
neointimal rupture. Compared with DES ＜ 20 months after implantation, DES ≥ 20 
months after implantation had a greater incidence of TCFA-like neointima (69% vs. 33%, p 
= 0.012) and red thrombi (27% vs. 0%, P = 0.007). Notably, there was a negative correlation 
between the thickness of the fibrous cap and follow-up period (r = -0.318, p = 0.024). 
Furthermore, unstable patients showed a thinner fibrous cap (55 μm vs. 100 μm, p = 0.006) 
and higher incidence of TCFA-like intima (75% vs. 37%, p = 0.008), intimal disruption 
(75% vs. 47%, p = 0.044), and thrombi (80% vs. 43%, p = 0.01) than stable patients. The 
authors concluded that in-stent neoatherosclerosis may be an important mechanism of 
DES failure, especially late after implantation. However, the majority (70%) of DES 
evaluated in this study were first-generation DES (SES and PES). Nakazawa et al reported 
on pathological change in a registry series of 299 autopsies with 406 coronary stented 
lesions, including 197 BMS and 209 DES. Neoatherosclerosis was defined as clusters of 
peristrut lipid-laden foamy macrophages within the neointima with or without necrotic 
core formation. The overall incidence of neoatherosclerosis was significantly higher in 
DES (31%) than in BMS (16%) lesions (p < 0.001). Neoatherosclerosis was found to be 
more frequent in DES than in BMS and to occur earlier in DES than in BMS. In addition, 
multiple logistic regression analysis revealed younger age, longer implant durations, DES 
usage, and underlying unstable plaques as independent predictors of neoatherosclerosis. 
However, all DES included in this pathological study were also SES (49%) and PES (51%). 
Because the vascular healing response after implantation may be influenced by the types 
of DES (different stent material, strut thickness, design, and polymer), long-term follow-
up OCT studies with a large number of second-generation DES (ZES and everolimus-
eluting stent) are needed to understand the differences in neointimal atherosclerotic 
change between the DES types. 
4. Limitation 
OCT abnormal findings inside the BMS and DES observed in these studies above may be 
similar to the features of vulnerable plaque in a native coronary artery. However, a direct 
comparison of OCT findings with histology is not done. In fact, there is a discrepancy in the 
frequency of neoatherosclerosis between OCT findings and pathological findings (Table 1). 
Therefore, histological data that properly validate OCT findings within the stents are 
required in the near future. 
5. Conclusion  
Neointima within the stent in both BMS and DES can transform into atherosclerotic tissue 
with time although it occurs earlier in DES than BMS. Neoathrosclerosis progression inside 
the implanted stents may be associated with very late coronary events such as VLST after 
BMS and DES implantation.  
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